**Coeptis Leverages AI Innovations and Blockchain Initiatives to Enhance Operational Efficiency and Drive Strategic Growth** WEXFORD, Pa. , Jan. 23, 2025 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical firm dedicated to advancing cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to share the expansion of its technological initiatives to incorporate state-of-the-art artificial intelligence and pioneering blockchain solutions. Building on the successful establishment of its Technology Division and the introduction of groundbreaking AI capabilities, Coeptis has shown considerable promise in improving operational efficiency and enhancing customer engagement. The Company acknowledges the vast potential for AI to transform the pharmaceutical industry while also investigating the possibilities offered by blockchain technology. Dave Mehalick, President and CEO of Coeptis, remarked, "We are excited to continue the momentum we’ve created with our Technology Division, especially in artificial intelligence, as we aim to boost our initiatives involving blockchain technology. This expansion reflects not only our commitment to staying at the cutting edge of technological advancements but also our resolve to pursue new opportunities that resonate with the rapidly changing digital landscape. " "The incorporation of blockchain initiatives into our Technology Division's offerings embodies Coeptis's mission to stay attuned to emerging trends and to seize new market opportunities for enhanced value delivery, " added Mr.

Mehalick. As we embark on this exciting new venture, we are confident in our capability to foster innovation and explore synergies that will benefit both our customers and shareholders. **About Coeptis Therapeutics Holdings, Inc. ** Coeptis Therapeutics Holdings, Inc. , along with its subsidiaries—including Coeptis Therapeutics, Inc. , Coeptis Pharmaceuticals, Inc. , GEAR Therapeutics, Inc. , and SNAP Biosciences, Inc. —is a biopharmaceutical and technology entity focused on developing cutting-edge cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to enhance treatment protocols and improve patient outcomes through its innovative research and development initiatives. The Company’s therapeutic portfolio is highlighted by assets licensed from Deverra Therapeutics, which encompass an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), along with GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and renowned researchers at the Karolinska Institute.